2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178714
    JNJ627 98%
    JNJ627 is a small molecule allosteric inhibitor of IL-17A with a KD of 92 nM. JNJ627 effectively inhibits the binding of IL-17A and IL-17RA, with an IC50 value of 16 nM. JNJ627 is capable of inhibiting the secretion of G-CSF (granulocyte colony-stimulating factor) caused by IL-17A stimulation. JNJ627 can be used for the study of autoimmune diseases (such as psoriasis).
    JNJ627
  • HY-178755
    DEL1187-126-5-80
    DEL1187-126-5-80 is a JAK3 inhibitor with IC50s of 52 and 7.9 nM against JAK3 WT in 0 and 60 min. DEL1187-126-5-80 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-5-80 can be used for the study of immune-mediated diseases.
    DEL1187-126-5-80
  • HY-178761
    PGK1-IN-1 3093312-81-0
    PGK1-IN-1 (Compound 6e) is a potent and selective PGK1 inhibitor (IC50: 33 nM). PGK1-IN-1 inhibits PGK1-mediated glycolytic metabolism and reduces glucose consumption/lactate production. PGK1-IN-1 enhances Nrf2 accumulation and HO-1 expression, and suppresses the transcription and protein levels of the inflammatory cytokines IL-1β and IL-6. PGK1-IN-1 ameliorates Dextran sulfate sodium (DSS) (HY-116282C)-induced experimental colitis in mice. PGK1-IN-1 can be used for research of inflammatory bowel disease (IBD).
    PGK1-IN-1
  • HY-178763
    DEL1187-126-28-16
    DEL1187-126-28-16 is a JAK3 inhibitor with IC50s of 10 and 0.97 nM against JAK3 WT in 0 and 60 min. DEL1187-126-28-16 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-28-16 can be used for the study of immune-mediated diseases.
    DEL1187-126-28-16
  • HY-178776
    DCLK1-IN-6
    DCLK1-IN-6 (Compound 12n) is a Doublecortin-like kinase 1 (DCLK1) inhibitor with an IC50 of 58 nM. DCLK1-IN-6 significantly inhibits DCLK1 enzyme activity and its mediated inflammatory pathway. DCLK1-IN-6 has remarkable anti-inflammatory activity and significantly alleviates symptoms in acute lung injury (ALI) and sepsis mouse models. DCLK1-IN-6 can be used for acute inflammation diseases research.
    DCLK1-IN-6
  • HY-178783
    MRS8454
    MRS8454 is a positive allosteric modulator (PAM) of the A3 adenosine receptor (A3AR). MRS8454 can significantly enhance the maximum effect of the standard agonist Cl-IB-MECA by approximately 286%-300%, and significantly reduce its EC50 value. MRS8454 effectively enhances the ability of A3AR agonists to inhibit the cAMP accumulation induced by Forskolin (HY-15371). MRS8454 can be used for the development of molecular probes.
    MRS8454
  • HY-178792
    TGI-15 3073601-32-5 98%
    TGI-15 is a highly selective prostaglandin F receptor antagonist. TGI-15 inhibits downstream signaling pathways by blocking the binding of PGF2 α to FP receptors. TGI-15 can be used for research on fibrotic and inflammatory conditions.
    TGI-15
  • HY-178793
    MrgprX2 antagonist-9 3095296-92-4
    MrgprX2 antagonist-9 (compound 10) is a potent Mas-related G protein-coupled receptor X2 (MrgprX2) antagonist with an IC50 value of 0.1-100 nM. MrgprX2 antagonist-9 has the potential for the research of inflammatory.
    MrgprX2 antagonist-9
  • HY-178794
    AGU661 3038861-75-2
    AGU661 is a Microsomal prostaglandin E2 synthase 1 (mPGES-1) inhibitor with an IC50 of 0.22  nM. AGU661 lowers PGE2 formation in human pro-inflammatory M1 macrophages and activated monocytes without affecting other lipid mediator pathways. AGU661 has unfavorable physicochemical properties with poor metabolic stability and strong plasma protein binding tendencies. AGU661 into PLGA-based NPs significantly enhances its bioactivity. AGU661 can be used for inflammatory disorders research.
    AGU661
  • HY-178795
    TEAD-IN-22 3034813-65-2 98%
    TEAD-IN-22 (compound I) is a TEAD inhibitor. TEAD-IN-22 has the potential for the research of cancer and fibrosis.
    TEAD-IN-22
  • HY-178796
    PROTAC LRRK2 Degrader-4 2839664-99-0
    PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC50 of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation. (Pink: LRRK2 ligand: LRRK2-IN-19 (HY-177016); Black: Linker (HY-178831); Blue: E3 ligand (HY-179222); E3+Linker (HY-178832).
    PROTAC LRRK2 Degrader-4
  • HY-178797
    PROTAC LRRK2 Degrader-3 3080678-98-1
    PROTAC LRRK2 Degrader-3 is a PROTAC LRRK2 degrader with a DC50 of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation. (Pink: LRRK2 ligand: LRRK2-IN-19 (HY-177016); Black: Linker (HY-178830); Blue: E3 ligand (HY-163927); E3+Linker (HY-178828)).
    PROTAC LRRK2 Degrader-3
  • HY-178825
    LD-110
    LD-110 is a highly efficient and effective PROTAC degrader targeting LSD1 (DC50 = 0.44 μM). LD-110 promotes LSD1 degradation and increases the level of H3K4 dimethylation in a ubiquitin-proteasome-dependent manner. LD-110 inhibits the growth and survival of multiple esophagus squamous cancer cell (ESCC) lines by inducing apoptosis. LD-110 can be used for the study of esophagus squamous cancer. Red: LSD1 ligand (HY-178826); Blue: E3 ligase CRBN ligand (HY-14658); Black: Linker (HY-N2578).
    LD-110
  • HY-178826
    LSD1-IN-45
    LSD1-IN-45 is an LSD1 inhibitor and a ligand for the target protein for PROTAC. LSD1-IN-45 can be used to synthesize PROTAC LD-110 (HY-178825).
    LSD1-IN-45
  • HY-178827
    Thalidomide-NH-C4 1809556-65-7
    Thalidomide-NH-C4 is an E3 ligase ligand-linker conjugate containing a CRBN ligand and a linker. Thalidomide-NH-C4 can bind to a target protein ligand to form a PROTAC molecule, LD-110 (HY-178825).
    Thalidomide-NH-C4
  • HY-178913
    Tyk2-IN-23 2734918-75-1
    Tyk2-IN-23 is a potent, orally active, selective TYK2 inhibitor (IC50 = 18 nM), exhibiting more than > 70-fold selectivity over JAK1/2/3 isoforms. Tyk2-IN-23 potently inhibits p-STAT3 in TYK2-dependent signaling activated by IFN-α and IL-10. Tyk2-IN-23 potently inhibits IFN-α-induced STAT1 phosphorylation in H9 cells. Tyk2-IN-23 can be used for the study of alopecia areata and allergic Rhinitis.
    Tyk2-IN-23
  • HY-178915
    ITA-5 2374162-36-2
    ITA-5 is a TBK1 inhibitor based on the structure of itaconic acid. can significantly inhibit the secretion of IFN-β. ITA-5 can inhibit the phosphorylation of TBK1, IRF3, and STAT1. ITA-5 can be used for research on autoimmune diseases and excessive inflammation.
    ITA-5
  • HY-178916
    ITA-9
    ITA-9 is a TBK1 inhibitor based on the structure of itaconic acid. ITA-9 can inhibit the IFN-I signaling pathway. ITA-9 can inhibit the phosphorylation of TBK1, IRF3, and STAT1. ITA-9 can be used for research on inflammatory reactions and tissue damage.
    ITA-9
  • HY-178919
    N-19004 2996841-28-0
    N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa.
    N-19004
  • HY-178926
    RAGE406R 3034560-21-6
    RAGE406R is an orally active RAGE-DIAPH1 interaction antagonist. RAGE406R can bind to ctRAGE and prevent the formation of the RAGE-DIAPH1 complex and inhibit its interaction. RAGE406R can reduce the expression of CCL2, TNF, and IL-6 in THP1 cells. RAGE406R suppresses delayed-type hypersensitivity in T2D mice. RAGE406R can be used for the study of diabetes.
    RAGE406R
Cat. No. Product Name / Synonyms Application Reactivity